NovaBiotics Ltd is a leading clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases.
We are in the midst of a worsening global antimicrobials resistance (AMR) crisis. There is an urgent need for new classes of antibacterial, antifungal and other antimicrobial treatments to address range of challenging infectious diseases that can no longer be resolved with existing drugs. NovaBiotics is a leading innovator in the anti-infectives space and we are designing and developing new medicines that are potential solutions not only to the AMR crisis, but also for complex diseases with an infectious component such as the respiratory infections associated with cystic fibrosis (CF).
NovaBiotics was founded by our CEO, Dr. Deborah O’Neil in 2004 and operates from sites in Aberdeen, UK (R&D headquarters), Dublin, Ireland and Boston (MA), U.S. The Company has a successful track record of invention to clinic of its portfolio of therapeutic candidates. These first in class antimicrobials have been developed from our two proprietary Technology platforms which are underpinned by an extensive, wholly owned intellectual property estate.
The Company’s advanced portfolio of antimicrobial therapeutic candidates targets large and important markets with significant unmet clinical needs, including NM002 (Nylexa®), an antibiotic potentiator for drug resistant bacterial infections including the secondary bacterial infections associated with COVID-19, NM001 (Lynovex®), an orphan drug candidate for cystic fibrosis (CF) and NP339, a novel antifungal peptide in development primarily for the treatment of invasive fungal diseases caused by mould & emerging, drug resistant yeasts. NP423 (Novarifyn®) is a bactericidal peptide for difficult to treat Gram negative and Gram positive bacteria and NP213 (Novexatin®), a potential step change therapy for onychomycosis.
Further information on NovaBiotics Ltd is available at: http://www.novabiotics.co.uk
“The Townsend family first invested in NovaBiotics in 2006 and has continued to support the company as a major cornerstone funder, both through further investments and by introducing other ‘High Net Worth’ individuals. This has been key in enabling NovaBiotics to successfully develop the company’s exciting pipeline of antimicrobial therapy candidates and most recently, in advancing Nylexa®, NovaBiotics’ potentially game-changing treatment for COVID-19. Ian Townsend has also supported the company in a personal capacity and helped us overcome many challenges whilst serving on the Board of the Company since 2011.
Without the belief and support of our shareholders and all our stakeholders, Nylexa® and our exciting pipeline of antibacterial and antifungal therapies would not be where they are today”.
Dr. Deborah O’Neil, CEO & CSO, Founder – NovaBiotics Ltd